

## Research Article

# Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia

Dawei Cui <sup>1</sup>, Yan Lv,<sup>1</sup> Xinwang Yuan,<sup>2</sup> Guoxiang Ruan,<sup>1</sup> Yu Zhang,<sup>3</sup> Cuilin Yan,<sup>4</sup> Dandan Xu,<sup>1</sup> Mengen Lv,<sup>1</sup> Yun Mao,<sup>1</sup> Jianping Cao,<sup>1</sup> Jie Jin,<sup>5</sup> and Jue Xie <sup>1</sup>

<sup>1</sup>Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

<sup>2</sup>Department of Laboratory Medicine, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China

<sup>3</sup>Department of Haematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China

<sup>4</sup>Department of Laboratory Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

<sup>5</sup>Department of Haematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

Correspondence should be addressed to Jue Xie; [zyyyxj2011@zju.edu.cn](mailto:zyyyxj2011@zju.edu.cn)

Received 16 October 2018; Revised 19 January 2019; Accepted 12 February 2019; Published 3 March 2019

Academic Editor: Alvaro González

Copyright © 2019 Dawei Cui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Background.** OX40, which is also known as tumor necrosis factor receptor superfamily member 4 (TNFRSF4), and its ligand (OX40L) play a critical role in the pathogenesis of autoimmune diseases. Immune thrombocytopenia (ITP), a hemorrhagic autoimmune disorder, is characterized by low platelet counts that are predominantly caused by antiplatelet autoantibodies. In this study, we firstly investigated the clinical significance of OX40 and OX40L expression in the pathogenesis of ITP in patients. **Methods.** Fifty-four newly diagnosed ITP patients and 24 healthy controls (HCs) were enrolled in this study. The percentage of OX40<sup>+</sup>CD4<sup>+</sup>T cells among CD4<sup>+</sup>T cells was analyzed by flow cytometry, and the expression levels of OX40 and OX40L mRNA were analyzed by quantitative real-time PCR. Plasma soluble OX40L (sOX40L) levels were analyzed by ELISA, and plasma levels of antiplatelet autoantibodies were analyzed by a solid-phase technique. **Results.** Compared with HCs, the frequencies of OX40<sup>+</sup>CD4<sup>+</sup>T cells were significantly increased in ITP patients, particularly in patients with positive antiplatelet autoantibodies compared to those with negative antiplatelet autoantibodies. The elevated frequencies of OX40<sup>+</sup>CD4<sup>+</sup>T cells were negatively correlated with low platelet counts in patients with positive antiplatelet autoantibodies. Plasma sOX40L levels in ITP patients were significantly greater than those in HCs and increased in patients with positive antiplatelet autoantibodies compared to those with negative antiplatelet autoantibodies. Plasma sOX40L levels were negatively correlated with low platelet counts in patients with positive antiplatelet autoantibodies. Additionally, the mRNA expression levels of OX40 and OX40L in PBMCs from ITP patients were also notably greater than those from HCs, and the expression levels of OX40 and OX40L were significantly different in ITP patients with positive and negative antiplatelet autoantibodies. **Conclusion.** These data indicated that increased expression levels of OX40 and OX40L were involved in the pathogenesis of ITP, and OX40 and OX40L may be valuable therapeutic targets for ITP.

## 1. Introduction

Immune thrombocytopenia (ITP) is a hemorrhagic autoimmune disease characterized by low platelet counts and an increased risk of bleeding [1–3]. Antiplatelet autoantibodies are the most causative agents for ITP, and antiplatelet autoantibodies can enhance platelet destruction and impair platelet generation by megakaryocytes [3–5]. The diagnosis of ITP

relies on clinical features and laboratory examinations and excludes other factors involved in thrombocytopenia [4–6]. Typical characteristics of ITP patients are skin petechiae and bleeding in mucosal, gastrointestinal, or intracranial regions [5–7]. The most important diagnostic criterion for ITP is a low peripheral platelet count (below  $100 \times 10^9/L$ ) [2, 6, 8]. The incidence of ITP is approximately 1.9~6.4 per  $10^5$  children/year and 3.3~3.9 per  $10^5$  adults/year, and the

morbidity is gradually increasing [6]. The classification of ITP includes primary and secondary ITP: primary ITP is defined by unclear causes and secondary ITP is caused by clear diseases, treatments, and other etiological factors [4, 6, 8].

OX40 (CD134), which is also known as tumor necrosis factor receptor superfamily member 4 (TNFRSF4), is expressed primarily on activated T cells, including CD4 and CD8 cells, and is also expressed at low levels on natural killer cells (NK) and natural killer T cells [9–11]. OX40 is not constitutively expressed on naïve T cells but is induced by antigen (Ag) stimulation and other signals, including CD28 ligation, CD40-CD40L ligation, and IL-2 [11–13]. The cognate ligand of OX40, OX40L (CD134L or CD252), which is also known as tumor necrosis factor superfamily member 4 (TNFSF4), is predominantly expressed on antigen-presenting cells (APCs), such as dendritic cells (DCs), B cells, and macrophages, and is also expressed on several immune cells, including vascular endothelial cells, mast cells, and activated CD4<sup>+</sup> and CD8<sup>+</sup> T cells [13–15]. OX40L expression is promoted by Ag stimulation and other factors, including prostaglandin E2, thymic stromal lymphopoietin (TSLP), and IL-18 [13, 16–18]. The interplay between OX40 and OX40L contributes to T cell survival, memory, and differentiation, promotes effector cytokine secretion, and reduces regulatory T cell function [12, 13, 15, 19, 20]. The interactions of the OX40/OX40L axis play a crucial role in the pathogenesis of autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), allergic asthma, and type 1 diabetes mellitus (T1DM) [19–24]. However, the role of OX40 and OX40L remains unclear in the pathogenesis of ITP.

In this study, we firstly evaluated the expression levels of OX40 and OX40L in primary ITP patients. The frequency of OX40<sup>+</sup>CD4<sup>+</sup>T cells among CD4<sup>+</sup>T cells, the plasma concentration of sOX40L protein, and OX40 and OX40L mRNA expression levels in PBMCs were significantly increased in primary ITP patients compared with healthy controls (HCs), and their expression was involved in low platelet counts and antiplatelet autoantibodies of ITP patients.

## 2. Materials and Methods

**2.1. Patients.** Between March and September 2018, fifty-four primary ITP patients were enrolled from the Department of Hematology of the First Affiliated Hospital, Zhejiang University School of Medicine, and the First Affiliated Hospital, Zhejiang Chinese Medical University. Twenty-four sex- and age-matched healthy controls (HCs) were recruited from the Healthy Management Center of the First Affiliated Hospital, Zhejiang University School of Medicine. All ITP patients were diagnosed according to consensus guidelines, and the patients and HCs who had cardiovascular disease, diabetes, pregnancy, obesity, infections, or connective tissue diseases were excluded from our study [3]. The median age of patients at the onset of primary ITP and the median age of the HCs were 37 (range, 19–66) and 37 years old (range, 20–68), respectively. The ITP patients had a median platelet count of  $43 \times 10^9/L$  ranging from 6

to  $77 \times 10^9/L$ . Furthermore, the platelet counts in the healthy individuals ranged from 171 to  $318 \times 10^9/L$  with a median count of  $247 \times 10^9/L$ . The main characteristics of these cases are shown in Table 1. This study was approved by the Institutional Research Ethics Committee of the First Affiliated Hospital of Zhejiang University, and informed consent was obtained from all patients and control subjects that were included in this study.

**2.2. Plasma and Peripheral Blood Mononuclear Cell Isolation.** Human fresh peripheral whole blood specimens were obtained from ITP patients and HCs. Plasma was isolated by centrifugation at  $1800 \times g$  for 10 min and was stored at  $-80^\circ C$  until use. Then, the remaining blood components were diluted with an equal volume of PBS for the following isolation of peripheral blood mononuclear cells (PBMCs) by density gradient centrifugation with Ficoll-Hypaque solution (CL5020, CEDARLANE, the Netherlands).

**2.3. Detection of Antiplatelet Autoantibodies.** For the ITP patients and HCs, antiplatelet autoantibodies were analyzed according to the platelet crossmatch protocol (MASPAT kit; K1360; Sanquin, Amsterdam, the Netherlands) described in a previous report [5]. Briefly, a monolayer of donor platelets was immobilized by centrifugation onto the surfaces of microplate wells coated with a platelet-specific mouse monoclonal antibody. Patient plasma was incubated in the appropriate wells. After incubation, unbound plasma components were removed by washing three times. Platelet-bound antibodies were analyzed by adding mouse monoclonal anti-human IgG- and human IgG-sensitized erythrocytes. A positive reaction was indicated by the adherence of red cells containing the MASPAT indicator throughout the well surface, whereas a negative reaction was indicated by discrete pellets of red cells containing the MASPAT indicator in the middle of the well. The experiment was conducted in triplicate.

**2.4. Detection of Plasma sOX40L.** Plasma levels of sOX40L were analyzed by a Quantikine Human OX40 Ligand ELISA Kit (R&D Systems, Minneapolis, MN, USA) in accordance with the manufacturer's protocol.

**2.5. Flow Cytometry Analysis.** Human PBMCs were transferred to sterile tubes and washed twice with phosphate-buffered saline (PBS) and then immunostained with APC-conjugated anti-human OX40 and FITC-conjugated anti-human CD4 (BioLegend, San Diego, CA). Isotype-matched antibody controls were used in this study. All staining procedures were performed according to the manufacturers' protocols, and the stained cells were analyzed by a BD FACSCalibur flow cytometer and CellQuest software (Becton Dickinson, Sparks, MD, USA).

**2.6. Total RNA Extraction and Quantitative Real-Time PCR.** To analyze the mRNA expression of OX40 and OX40L in human PBMCs from patients, total RNA was extracted by the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Next, cDNA was synthesized by a PrimeScript™ II 1st Strand

TABLE 1: The clinical characteristics of primary ITP patients and HCs.

| Clinical features                          | ITP        | HCs           |
|--|------------|---------------|
| Number                                     | 54         | 24            |
| Gender (M/F)                               | 15/39      | 7/17          |
| Age (range)                                | 37 (19-66) | 37 (20-68)    |
| Antiplatelet autoantibody (-/+)            | 32/22      | 24/0          |
| Platelet count (range) ( $\times 10^9/L$ ) | 43 (6-77)  | 247 (171-318) |

Note: M/F: male/female; ITP: immune thrombocytopenia; HCs: healthy controls.

cDNA Synthesis Kit (TaKaRa, Dalian, China) according to the manufacturer's protocol.

Real-time PCR was performed using TaKaRa SYBR Supermix (TaKaRa, Dalian, China) on an ABI 7500 analysis system (Applied Biosystems, Foster City, CA, USA). The amplification conditions were as follows: predenaturation ( $95^{\circ}\text{C}$  for 30 s), 40 cycles of denaturation ( $95^{\circ}\text{C}$  for 30 s), and annealing and extension ( $60^{\circ}\text{C}$  for 34 s). The primers were designed and synthesized with the following sequences: sense,  $5'$ -ACAACGACGTGGTCAGCTCCAA- $3'$ , and antisense,  $5'$ -CAGCGGCAGACTGTGTCCTGT- $3'$  (*OX40*); sense,  $5'$ -CCTACATCTGCCTGCACCTTCTC- $3'$ , and antisense,  $5'$ -TGATGACTGAGTTGTTCTGCACC- $3'$  (*OX40L*); and sense,  $5'$ -GTCTCCTCTGACTTCAACAGCG- $3'$ , and antisense,  $5'$ -ACCACCCTGTTGCTGTAGCCAA- $3'$  (*GAPDH*). The relative expression levels of the target genes were calculated by the comparative Ct method presented as  $2^{-\Delta\Delta\text{Ct}}$ . The experiments were conducted in triplicate.

**2.7. Statistical Analysis.** The data were analyzed using GraphPad Prism 5.0 software and SPSS 16.0 statistics software, and the descriptive data are presented as medians (ranges) for continuous variables. The data of differential expression between the ITP and control groups from the qRT-PCR assay were analyzed by unpaired Student's *t*-tests, and the results are presented as the mean  $\pm$  SEM. Correlations between variables were determined using Spearman's correlation coefficient. A *p* value  $< 0.05$  was considered to be statistically significant.

### 3. Results

**3.1. Detection of Antiplatelet Autoantibodies in ITP Patients.** In this study, 22 (41%) of 54 patients with primary ITP were positive for antiplatelet autoantibodies (Table 1). The platelet counts in patients with positive antiplatelet autoantibodies were significantly less than those in patients with negative antiplatelet autoantibodies and in the HCs (Figure 1).

**3.2. Expression of OX40 on CD4<sup>+</sup> T Cells in ITP Patients.** To investigate the potential role of OX40<sup>+</sup>CD4<sup>+</sup> T cells in ITP patients, the frequency of circulating OX40<sup>+</sup>CD4<sup>+</sup> T cells among CD4<sup>+</sup> T cells was analyzed by flow cytometry (Figure 2(a)). We analyzed OX40 expression gated on CD4<sup>+</sup> T cells from human PBMCs to delineate circulating




FIGURE 1: Detection of antiplatelet autoantibodies in ITP patients. Twenty-two (41%) of 54 patients with primary ITP were positive for antiplatelet autoantibodies detected by ELISA. The peripheral platelet counts in patients with positive antiplatelet autoantibodies (ITP(+)) and negative antiplatelet autoantibodies (ITP(-)) and in HCs. \*\*\**p*  $< 0.001$ ; \*\**p*  $< 0.01$ ; \**p*  $< 0.05$ .

OX40<sup>+</sup>CD4<sup>+</sup> T cells in peripheral blood from ITP patients and HCs. The frequencies of circulating OX40<sup>+</sup>CD4<sup>+</sup> T cells among CD4<sup>+</sup> T cells in ITP patients were significantly increased compared to those in HCs; in particular, the frequencies of circulating OX40<sup>+</sup>CD4<sup>+</sup> T cells in ITP patients with positive antiplatelet autoantibodies were notably greater than those in ITP patients with negative antiplatelet autoantibodies (Figure 2(b)). Interestingly, a significant negative correlation was observed between the frequency of OX40<sup>+</sup>CD4<sup>+</sup> T cells and peripheral platelet counts in ITP patients with positive antiplatelet autoantibodies (Figure 2(c)), but this correlation was not observed in ITP patients with negative antiplatelet autoantibodies (Figure 2(d)).

**3.3. Plasma Concentrations of Soluble OX40L in Patients.** To analyze the potential role of the OX40 ligand in ITP patients, plasma soluble OX40L (sOX40L) levels were measured by ELISA. The results showed that the concentrations of the plasma sOX40L protein in ITP patients were significantly greater than those in the HCs, and further analysis indicated that there was an obvious difference between ITP patients with positive and negative antiplatelet autoantibodies (Figure 2(a)). Moreover, the levels of the sOX40L protein were obviously correlated with platelet counts in ITP patients with positive antiplatelet autoantibodies (Figure 3(b)), but these parameters were not significantly related in ITP patients with negative antiplatelet autoantibodies (Figure 3(c)).

**3.4. Expression of OX40 and OX40L mRNA in PBMCs of Patients.** To further explore the expression of OX40 and OX40L in ITP patients, the expression levels of OX40 and OX40L mRNA in PBMCs of ITP patients and HCs were comparatively analyzed by quantitative real-time PCR. The results showed remarkably elevated expression levels of OX40 and OX40L mRNA in ITP patients compared with




FIGURE 2: The expression of OX40 on CD4<sup>+</sup> T cells in ITP patients. Peripheral blood mononuclear cells (PBMCs) from 54 patients with ITP and 24 healthy controls (HCs) were isolated and stained with labeled antibodies and analyzed by flow cytometry, as described in Section 2. (a) The cells were gated initially on lymphocytes and then on CD4<sup>+</sup> T cells. (b) The frequency of OX40<sup>+</sup>CD4<sup>+</sup> T cells among the total CD4<sup>+</sup> T cells from HCs and ITP patients. (c) The relationship between the frequency of OX40<sup>+</sup>CD4<sup>+</sup> T cells and peripheral platelet counts in ITP patients with positive antiplatelet autoantibodies. (d) The relationship between the frequency of OX40<sup>+</sup>CD4<sup>+</sup> T cells and peripheral platelet counts in ITP patients with negative antiplatelet autoantibodies. ITP(+): ITP patients with positive antiplatelet autoantibodies; ITP(-): ITP patients with negative antiplatelet autoantibodies. \*\*\* $p < 0.001$ ; \*\* $p < 0.01$ ; \* $p < 0.05$ .

the HCs; in particular, a noticeable difference was observed between ITP patients with positive and negative antiplatelet autoantibodies (Figures 4(a) and 4(b)).

#### 4. Discussion

ITP is a complex immune-mediated autoimmune disease characterized by a transient or persistent decreased platelet count due to the increased destruction and decreased production of platelets, which is predominantly caused by the antiplatelet autoantibody. Therefore, the antiplatelet autoantibody is a major causative factor for the pathogenetic mechanism of ITP [1–4]. Antiplatelet autoantibodies mediate platelet destruction by binding to platelet membrane glycoproteins (GPs), including GPIIb/IIIa, GPIb/IX, and GPIV, and impair or inhibit platelet production by megakaryocytes by specifically recognizing platelet antigens located on megakaryocytes (such as GPIb and GPIIb/IIIa) [3–7]. In our study, 40% of ITP patients had positive antiplatelet autoantibodies as well as low platelet counts in comparison with patients with negative antiplatelet autoantibodies, indicating that antiplatelet autoantibodies might aggravate platelet destruction and impair platelet production that causes reduced peripheral platelet counts. Accumulating evidence has shown

that some autoimmune diseases can be effectively relieved or even cured by decreasing autoantibody levels using drugs and/or plasma exchange treatments [25–27]. Therefore, we speculated that the disease severity of ITP in patients, specifically in those patients with positive antiplatelet autoantibodies, could be effectively improved or even cured by reducing antiplatelet autoantibody levels by some drug treatments and/or plasma exchange strategies.

Increasing evidence has demonstrated that the OX40-OX40L axis plays an important role in the pathogenesis of autoimmune diseases and is involved in autoantibody production [10–15]. For example, an increased expression level of OX40 on CD4<sup>+</sup> T cells is closely correlated with disease activity and lupus nephritis, and serum levels of OX40L are positively correlated with anti-dsDNA levels in SLE patients [13, 21, 28]. Plasma levels of soluble OX40L (sOX40L) and the percentages of OX40<sup>+</sup>CD4<sup>+</sup> T cells in PBMCs have been shown to be increased in early RA patients, and sOX40L levels have been shown to be strongly correlated with the levels of anticitrullinated protein antibodies (ACPAs) and IgM-rheumatoid factor (IgM-RF) [29]. Recent studies have indicated that OX40L expression on APCs can promote follicular helper T (Tfh) cell responses, which further exacerbate autoantibody




FIGURE 3: Plasma concentrations of soluble OX40L in patients. (a) Concentrations of plasma sOX40L in HCs and in ITP patients with negative and positive antiplatelet autoantibodies. (b) The relationship between the levels of plasma sOX40L and peripheral platelet counts in ITP patients with positive antiplatelet autoantibodies. (c) The relationship between the levels of plasma sOX40L and peripheral platelet counts in ITP patients with negative antiplatelet autoantibodies. ITP(+): ITP patients with positive antiplatelet autoantibodies; ITP(-): ITP patients with negative antiplatelet autoantibodies. \*\*\* $p < 0.001$ ; \*\* $p < 0.01$ ; \* $p < 0.05$ .




FIGURE 4: The expression of *OX40* and *OX40L* mRNA in PBMCs of patients. (a) The expression levels of *OX40* mRNA in PBMCs from 10 ITP patients with positive antiplatelet autoantibodies, 12 ITP patients with negative antiplatelet autoantibodies, and 12 HCs. (b) The expression levels of *OX40L* mRNA in PBMCs from 10 ITP patients with positive antiplatelet autoantibodies, 12 ITP patients with negative antiplatelet autoantibodies, and 12 HCs. ITP(+): ITP patients with positive antiplatelet autoantibodies; ITP(-): ITP patients with negative antiplatelet autoantibodies. \*\*\* $p < 0.001$ ; \*\* $p < 0.01$ ; \* $p < 0.05$ .

production [17, 19, 21, 30]. Therefore, the OX40-OX40L axis likely contributes to the generation of autoantibodies in many autoimmune diseases.

However, OX40 and OX40L expression remains completely unclear in ITP patients. In this study, we showed, for the first time, that the percentage of OX40<sup>+</sup>CD4<sup>+</sup> T cells among CD4<sup>+</sup> T cells was significantly increased in patients with primary ITP compared with the HCs. Plasma sOX40L levels were significantly increased in patients with primary ITP compared to the HCs. Therefore, these findings indicate the important role of OX40 and sOX40L proteins in the pathogenesis of ITP in patients. Furthermore, OX40 expression levels on CD4<sup>+</sup> T cells and sOX40L levels in ITP patients with positive antiplatelet autoantibodies were notably greater than those in ITP patients with negative autoantibodies. Interestingly, a negative correlation was observed between OX40<sup>+</sup>CD4<sup>+</sup> T cell frequencies and low platelet counts, and similar results were observed between sOX40L levels and low platelet counts in ITP patients. These results implied that increased OX40 (OX40L) expression levels possibly contributed to the production of antiplatelet autoantibodies that reduced peripheral platelet counts. Therefore, the OX40-OX40L axis possibly provides an amplification loop for the generation of antiplatelet autoantibodies in ITP patients. Furthermore, recent evidence has suggested that blocking the OX40-OX40L axis may be an effective strategy for ameliorating autoimmune diseases, including SLE, RA, colitis, and type 1 diabetes mellitus [13, 31–34]. Therefore, these results imply that the blockade of OX40-OX40L could be a potential therapeutic strategy for ITP.

Increasing studies have shown that upregulated OX40 mRNA expression in active CD4<sup>+</sup> T cells and downregulated OX40 mRNA expression in Treg cells play a critical role in T1DM [35]. OX40 mRNA expression has been shown to be upregulated in CD4<sup>+</sup> T cells from patients with active SLE [36]. Moreover, OX40 and OX40L mRNA expression levels are increased in the spleen, lymph node, and nervous tissue of experimental allergic neuritis (EAN) rats, but not in peripheral blood [13]. The deficiency in functional Roquin proteins increases the OX40 mRNA expression level and Tfh cell differentiation and causes lupus-like autoimmune disease in mice [30]. In this study, our results indicated that the expression levels of OX40 and OX40L mRNA in PBMCs from ITP patients were significantly increased compared to those in PBMCs from the HCs, and the expression levels of OX40 and OX40L mRNA were notably different between ITP patients with positive and negative antiplatelet autoantibodies. These findings further implied that upregulated OX40 and OX40L mRNA expression might play a crucial role in the pathogenesis of ITP.

## 5. Conclusion

In conclusion, our results showed aberrant expression of OX40 and OX40L in peripheral blood from primary ITP patients, and these findings were indicative of the important roles of OX40 and OX40L in the pathogenesis of ITP in patients. The OX40-OX40L axis likely affects the production of antiplatelet autoantibodies that further decrease

platelet counts by impairing and/or inhibiting platelet production. Therefore, the present study indicated that the OX40-OX40L axis may be a potential immune therapeutic target for ITP patients in the future. The investigation of a large number of ITP patients and basic experiments should be conducted to determine the roles of the OX40-OX40L axis in the pathogenesis of ITP in the future.

## Data Availability

All data generated or analyzed in this study are included in the present article.

## Conflicts of Interest

All authors declare that they have no competing interests.

## Authors' Contributions

Dawei Cui and Jue Xie designed the study, and Jue Xie, Dawei Cui, and Yan Lv drafted the manuscript. Xinwang Yuan, Cuilin Yan, Yun Mao, and Jianping Cao collected the clinical specimens and data. Dawei Cui, Yan Lv, Guoxiang Ruan, Dandan Xu, and Meng Lv performed the experiments. Jue Xie, Dawei Cui, Yan Lv, and Dandan Xu performed the statistical analysis. The diagnosis of ITP patients was performed by Professor Jie Jin and Dr. Yu Zhang. All authors have read and approved the final version of the manuscript.

## Acknowledgments

We gratefully thank Shenghua Yang and Yahong Wu (Clinical Research Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China) for providing technology services for flow cytometry in our study. We quite thank American Journal Experts (AJE) for providing English language editing services to our manuscript. This study was supported by grants from the National Natural Science Foundation of China (81871709 and 91846103) and the Natural Science Foundation of Zhejiang Province of China (LY16H200001 and LY13H080001).

## References

- [1] D. B. Cines and V. S. Blanchette, "Immune thrombocytopenic purpura," *The New England Journal of Medicine*, vol. 346, no. 13, pp. 995–1008, 2002.
- [2] E. Lo and S. Deane, "Diagnosis and classification of immune-mediated thrombocytopenia," *Autoimmunity Reviews*, vol. 13, no. 4-5, pp. 577–583, 2014.
- [3] J. Yu, M. Hua, X. Zhao et al., "NF- $\kappa$ B-94ins/del ATTG genotype contributes to the susceptibility and imbalanced Th17 cells in patients with immune thrombocytopenia," *Journal of Immunology Research*, vol. 2018, Article ID 8170436, 12 pages, 2018.
- [4] S. Audia, M. Mahévas, M. Samson, B. Godeau, and B. Bonnotte, "Pathogenesis of immune thrombocytopenia," *Autoimmunity Reviews*, vol. 16, no. 6, pp. 620–632, 2017.

- [5] J. Xie, D. Cui, Y. Liu et al., "Changes in follicular helper T cells in idiopathic thrombocytopenic purpura patients," *International Journal of Biological Sciences*, vol. 11, no. 2, pp. 220–229, 2015.
- [6] M. Swinkels, M. Rijkers, J. Voorberg, G. Vidarsson, F. W. G. Leebeek, and A. J. G. Jansen, "Emerging concepts in immune thrombocytopenia," *Frontiers in Immunology*, vol. 9, p. 880, 2018.
- [7] J. Li, J. A. Sullivan, and H. Ni, "Pathophysiology of immune thrombocytopenia," *Current Opinion in Hematology*, vol. 25, no. 5, pp. 1–381, 2018.
- [8] X. G. Liu, X. C. Bai, F. P. Chen et al., "Chinese guidelines for treatment of adult primary immune thrombocytopenia," *International Journal of Hematology*, vol. 107, no. 6, pp. 615–623, 2018.
- [9] T. Yoshioka, A. Nakajima, H. Akiba et al., "Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis," *European Journal of Immunology*, vol. 30, no. 10, pp. 2815–2823, 2000.
- [10] M. Croft, T. So, W. Duan, and P. Soroosh, "The significance of OX40 and OX40L to T-cell biology and immune disease," *Immunological Reviews*, vol. 229, no. 1, pp. 173–191, 2009.
- [11] M. Croft, "Control of immunity by the TNFR-related molecule OX40 (CD134)," *Annual Review of Immunology*, vol. 28, no. 1, pp. 57–78, 2010.
- [12] G. Kinnear, K. J. Wood, F. Fallah-Arani, and N. D. Jones, "A diametric role for OX40 in the response of effector/memory CD4+T cells and regulatory T cells to alloantigen," *Journal of Immunology*, vol. 191, no. 3, pp. 1465–1475, 2013.
- [13] G. J. Webb, G. M. Hirschfield, and P. J. L. Lane, "OX40, OX40L and autoimmunity: a comprehensive review," *Clinical Reviews in Allergy & Immunology*, vol. 50, no. 3, pp. 312–332, 2016.
- [14] M. J. Gough and A. D. Weinberg, "OX40 (CD134) and OX40L," *Advances in Experimental Medicine and Biology*, vol. 647, pp. 94–107, 2009.
- [15] N. Ishii, T. Takahashi, P. Soroosh, and K. Sugamura, "OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology," *Advances in Immunology*, vol. 105, pp. 63–98, 2010.
- [16] P. Krause, M. Bruckner, C. Uermosi, E. Singer, M. Groettrup, and D. F. Legler, "Prostaglandin E2 enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells," *Blood*, vol. 113, no. 11, pp. 2451–2460, 2009.
- [17] L. Pattarini, C. Trichot, S. Bogiatzi et al., "TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand," *The Journal of Experimental Medicine*, vol. 214, no. 5, pp. 1529–1546, 2017.
- [18] J. R. Maxwell, R. Yadav, R. J. Rossi et al., "IL-18 bridges innate and adaptive immunity through IFN- $\gamma$  and the CD134 pathway," *Journal of Immunology*, vol. 177, no. 1, pp. 234–245, 2006.
- [19] C. Jacquemin, N. Schmitt, C. Contin-Bordes et al., "OX40 ligand contributes to human lupus pathogenesis by promoting T follicular helper response," *Immunity*, vol. 42, no. 6, pp. 1159–1170, 2015.
- [20] M. Croft and R. M. Siegel, "Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases," *Nature Reviews Rheumatology*, vol. 13, no. 4, pp. 217–233, 2017.
- [21] J. Sitrin, E. Suto, A. Wuster et al., "The Ox40/Ox40 ligand pathway promotes pathogenic Th cell responses, plasmablast accumulation, and lupus nephritis in NZB/W F1 mice," *Journal of Immunology*, vol. 199, no. 4, pp. 1238–1249, 2017.
- [22] J. Jiang, C. Liu, M. Liu et al., "OX40 signaling is involved in the autoactivation of CD4+CD28- T cells and contributes to the pathogenesis of autoimmune arthritis," *Arthritis Research & Therapy*, vol. 19, no. 1, p. 67, 2017.
- [23] Q. Wu, Y. Tang, X. Hu et al., "Regulation of Th1/Th2 balance through OX40/OX40L signalling by glycyrrhizic acid in a murine model of asthma," *Respirology*, vol. 21, no. 1, pp. 102–111, 2016.
- [24] C. S. Haddad, P. Bhattacharya, K. Alharshawi et al., "Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice," *Autoimmunity*, vol. 49, no. 5, pp. 298–311, 2016.
- [25] P. Ulrichts, A. Guglietta, T. Dreier et al., "Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans," *The Journal of Clinical Investigation*, vol. 128, no. 10, pp. 4372–4386, 2018.
- [26] B. Fattizzo, A. Zaninoni, F. Nesa et al., "Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias," *American Journal of Hematology*, vol. 90, no. 8, pp. E149–E151, 2015.
- [27] C. B. Chighizola, L. Andreoli, M. Gerosa, A. Tincani, A. Ruffatti, and P. L. Meroni, "The treatment of antiphospholipid syndrome: a comprehensive clinical approach," *Journal of Autoimmunity*, vol. 90, pp. 1–27, 2018.
- [28] Y. B. Zhou, R. G. Ye, Y. J. Li, C. M. Xie, and Y. H. Wu, "Effect of anti-CD134L mAb and CTLA4Ig on ConA-induced proliferation, Th cytokine secretion, and anti-dsDNA antibody production in spleen cells from lupus-prone BXSB mice," *Autoimmunity*, vol. 41, no. 5, pp. 395–404, 2009.
- [29] J. K. Laustsen, T. K. Rasmussen, K. Stengaard-Pedersen et al., "Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis," *Arthritis Research & Therapy*, vol. 16, no. 5, p. 474, 2014.
- [30] K. U. Vogel, S. L. Edelmann, K. M. Jeltsch et al., "Roquin paralogs 1 and 2 redundantly repress the Icos and Ox40 costimulator mRNAs and control follicular helper T cell differentiation," *Immunity*, vol. 38, no. 4, pp. 655–668, 2013.
- [31] S. Kshirsagar, E. Binder, M. Riedl, G. Wechselberger, E. Steichen, and M. Edelbauer, "Enhanced activity of Akt in T<sub>H</sub>17 cells from children with lupus nephritis is associated with reduced induction of tumor necrosis factor receptor-associated factor 6 and increased OX40 expression," *Arthritis and Rheumatism*, vol. 65, no. 11, pp. 2996–3006, 2013.
- [32] E. Gwyer Findlay, L. Danks, J. Madden et al., "OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis," *Proceedings of the National Academy of Sciences*, vol. 111, no. 6, pp. 2289–2294, 2014.
- [33] T. Griseri, M. Asquith, C. Thompson, and F. Powrie, "OX40 is required for regulatory T cell-mediated control of colitis," *The Journal of Experimental Medicine*, vol. 207, no. 4, pp. 699–709, 2010.
- [34] M. Honkanen-Scott, J. Johnson, B. Hering, and P. Bansal-Pakala, "Blockade of OX40 signals enhance survival of xenografts in spontaneously diabetic NOD mice," *Transplantation Proceedings*, vol. 40, no. 2, pp. 483–485, 2008.

- [35] W. Łuczyński, A. Stasiak-Barmuta, A. Juchniewicz et al., "The mRNA expression of pro- and anti-inflammatory cytokines in T regulatory cells in children with type 1 diabetes," *Folia Histochemica et Cytobiologica*, vol. 48, no. 1, pp. 93–100, 2010.
- [36] P. Rajabi, M. Alaei, K. Mousavizadeh, and A. Samadikuchaksaraei, "Altered expression of TNFSF4 and TRAF2 mRNAs in peripheral blood mononuclear cells in patients with systemic lupus erythematosus: association with atherosclerotic symptoms and lupus nephritis," *Inflammation Research*, vol. 61, no. 12, pp. 1347–1354, 2012.





**Hindawi**

Submit your manuscripts at  
[www.hindawi.com](http://www.hindawi.com)

